Sign in Subscribe
Cancer

MAIA Biotechnology Announces Enrolment of First Patients in Part C of THIO-101 Phase 2 Clinical Trial

Strategic Insights

— 2 min read

The American Association for Cancer Research (AACR), the National Cancer Institute (NIC), and the European Organisation for Research and Treatment of Cancer (EORTC) hosted the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. MAIA Biotechnology's Sr. Medical Director, Victor Zaporojan, presented a Trial in Progress poster titled "A Phase 2 Study of Ateganosine (THIO; 6-thio-2'-deoxyguanosine) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Resistant to Prior ICI and Chemotherapy: THIO-101 Trial in Progress." Dr. Zaporojan stated that the company has enrolled five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 trial.

MAIA's Trial in Progress poster highlighted the safety profile of ateganosine, which has shown to be well-aligned with Parts A and B. The company also announced that they are continuing to enroll patients in the expansion phase of the clinical trial in Europe and Asia. The expansion phase aims to assess overall response rates (ORR) in advanced NSCLC patients receiving third-line therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy.

The high prevalence of smoking, compounded by air pollution, is the key driver of NSCLC in Turkey. According to a 2018 study, tobacco smoking accounted for 89.6% of lung cancer cases in Turkey. Subsequent research in 2019 suggested that prolonged exposure to ambient air pollution may have contributed to around 15% of lung cancer-related deaths in Turkey.

Key Takeaways:

  • MAIA Biotechnology has enrolled five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 clinical trial.
  • The company's Sr. Medical Director, Victor Zaporojan, presented a Trial in Progress poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
  • The safety profile of ateganosine has shown to be well-aligned with Parts A and B of the clinical trial.
  • MAIA is continuing to enroll patients in the expansion phase of the clinical trial in Europe and Asia.
  • The expansion phase aims to assess overall response rates (ORR) in advanced NSCLC patients receiving third-line therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy.
  • Tobacco smoking accounted for 89.6% of lung cancer cases in Turkey, while prolonged exposure to ambient air pollution may have contributed to around 15% of lung cancer-related deaths in Turkey.

Statistics:

  • 5 patients enrolled in the expansion phase of the THIO-101 Phase 2 clinical trial from Taiwan and Turkey.
  • 89.6% of lung cancer cases in Turkey were attributed to tobacco smoking (2018 study).
  • 15% of lung cancer-related deaths in Turkey may have been contributed by prolonged exposure to ambient air pollution (2019 study).

Sources:

  • GLOBE NEWSWIRE: "MAIA Biotechnology Announces Attendance at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"
  • ClinicalTrials.gov: "A Phase 2 Study of Ateganosine (THIO; 6-thio-2'-deoxyguanosine) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Resistant to Prior ICI and Chemotherapy: THIO-101 Trial in Progress"
  • International Society for the Prevention of Tobacco Induced Diseases (TID): "14th Annual Conference of the International Society for the Prevention of Tobacco Induced Diseases (TID)"
  • Trakya University, Faculty of Medicine, Turkiye: Research on the impact of air pollution on lung cancer-related deaths.

Read more